Stocktoria
Replimune Group, Inc. REPL
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-07-20
Chart by TradingView
2/9
Piotroski F — financial health
-0.42
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$261.6M | -$234.8M | -$177.1M | -$118.3M | -$80.0M |
| Net income | -$247.3M | -$215.8M | -$174.3M | -$118.0M | -$80.9M |
| Operating cash flow | -$192.2M | -$185.5M | -$128.1M | -$82.2M | -$61.4M |
| Free cash flow | — | — | -$130.3M | -$84.5M | -$63.8M |
| Total assets | $551.3M | $487.7M | $646.6M | $461.2M | $543.1M |
| Total liabilities | $135.5M | $113.2M | $91.3M | $50.0M | $44.4M |
| Shareholders' equity | $415.8M | $374.5M | $555.3M | $411.2M | $498.7M |
| Ratios | |||||
| Return on assets | -44.9% | -44.2% | -27.0% | -25.6% | -14.9% |
| Return on equity | -59.5% | -57.6% | -31.4% | -28.7% | -16.2% |
| Debt / equity | 0.11× | 0.12× | 0.05× | 0.00× | — |
| Current ratio | 7.95 | 10.72 | 17.52 | 19.46 | 33.25 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 381,453 | $2.9M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.42 (distress)
- Working capital / assets 0.786
- Retained earnings / assets -1.721
- EBIT / assets -0.475
- Equity / liabilities 3.069
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001737953 · as of 2025-03-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.